Navigation Links
Patients Taking VIMOVO(TM) Showed a Decrease in Incidence of NSAID-Associated Ulcers
Date:10/19/2009

PHILADELPHIA, Oct. 19 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) and POZEN Inc. (Nasdaq: POZN) today announced pivotal data from two POZEN clinical trials that were presented at the American College of Rheumatology (ACR) 2009 Annual Scientific Meeting in Philadelphia, PA.

The data demonstrated that patients at risk for developing NSAID-associated gastric ulcers taking VIMOVO(TM) (naproxen/esomeprazole magnesium, formerly known as PN 400) experienced significantly fewer endoscopically confirmed gastric ulcers (GU) compared with patients taking enteric-coated (EC) naproxen (500 mg) alone. Data from study PN400-301 showed a 4.1% incidence of GU in patients taking VIMOVO, compared to 23.1% among patients taking EC naproxen (p<0.001). Study PN400-302 showed a 7.1% incidence of GU among patients taking VIMOVO, compared to 24.3% with EC naproxen (p<0.001).

VIMOVO is a fixed-dose combination of enteric-coated naproxen, a non-steroidal anti-inflammatory drug (NSAID) and immediate release esomeprazole, a proton pump inhibitor (PPI), under investigation for the treatment of the signs and symptoms of osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis (AS) in patients who are at risk of developing NSAID-associated gastric ulcers.

"These results provide new information about VIMOVO and the incidence of NSAID-induced endoscopically confirmed gastric ulcers in patients with osteoarthritis," said Marc C. Hochberg, M.D., M.P.H., professor of medicine and head of the Division of Rheumatology and Clinical Immunology, University of Maryland School of Medicine in Baltimore, and co-principal investigator for the study. "If approved, VIMOVO will provide arthritis patients at risk for NSAID associat
'/>"/>

SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ULORIC(R) (febuxostat) Demonstrated Efficacy for Management of Hyperuricemia in Patients with Gout
2. U.S. Food and Drug Administration Approves CRESTOR(R) for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia
3. Data from Jazz Pharmaceuticals First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia to be Presented at Upcoming Conferences
4. New Data Showed Type 2 Diabetes Patients Experienced Greater Blood Sugar Reductions when Treated with ACTOplus met(R) (pioglitazone HCl and metformin HCl) as Initial Therapy Compared to Either Component Alone
5. Breast Cancer Survivors and Patients Encouraged to Have Medical History Readily Available
6. Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment
7. Fresenius Medical Care, N.A. Has Selected VitalRemedyMDs VitalProteinRx(TM) As Its Bar of Choice for Protein Replacement in Dialysis Patients
8. Results Published In Journal of Cystic Fibrosis Confirm CREON(R) (pancrelipase) Delayed-Release Capsules Improves Fat Absorption in Patients With Cystic Fibrosis
9. Breast-Specific Gamma Imaging Proves Cost-Effective for Pre-Surgical Planning of Patients with Known Cancer Diagnosis
10. Latest Content Release for The T SystemEV EDIS Supports Clinicians in Providing Quality Care for H1N1 Patients
11. Outcomes Registry in Heart Attack Patients to Generate Numerous Studies; Data Quality Ensured Through Velos Clinical Research Management System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , September 19, 2014 ... by Equipment Type (Benchtop, Mobile, Industrial, & Laboratory), ... Technology (Tray-style, Manifold, & Rotary) & Geography - ... MarketsandMarkets, defines and segments the lyophilization market on ... with analyses and projections of the market size ...
(Date:9/19/2014)... Fla. , Sept. 19, 2014  The body ... with the publication of two papers this past week.  ... – Head and Neck Surgery , finds that ... and subjective measures of sleep disordered breathing, leading the ... reduction in obstructive sleep apnea severity and improvement of ...
(Date:9/19/2014)... and CAMBRIDGE, Mass. , Sept. 19, ... (PGDx), a provider of advanced cancer genome analysis ... a leader in discovering and developing highly selective ... the first-ever comprehensive genomic study of malignant mixed ... of the female reproductive system, also known as ...
Breaking Medicine Technology:Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
... Medical, Inc., the wholly-owned operating subsidiary of Patient ... the recently released 2011-2012 U.S. News and World ... of the SurgiCount Safety-Sponge® System, a clinically proven ... common surgical errors, retained surgical sponges.  Only 17 ...
... A new policy recommendation released on 20 July by ... of serological (blood) tests to diagnose active tuberculosis (TB). ... are different to QuantiFERON, which measures responses of white ... Active tuberculosis occurs when the TB organism has overcome ...
Cached Medicine Technology:SurgiCount Medical Announces Expanded Honor Roll Hospital Users, Landmark Product Usage Milestones Achieved 2SurgiCount Medical Announces Expanded Honor Roll Hospital Users, Landmark Product Usage Milestones Achieved 3Cellestis Responds to World Health Organization Guidance on Use of Blood Tests for Active Tuberculosis 2Cellestis Responds to World Health Organization Guidance on Use of Blood Tests for Active Tuberculosis 3Cellestis Responds to World Health Organization Guidance on Use of Blood Tests for Active Tuberculosis 4
(Date:9/19/2014)... leading Dartmouth researcher, working with The Melanoma Genetics Consortium, ... today in the Journal of the National Cancer ... of melanoma. , "For the first time, we have ... telomeres play a part in the risk of developing ... PhD, School of Medicine at the University of Leeds ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 According to ... of the embattled blood-thinner Xarelto, named as defendants in ... Common Pleas, have moved the court to dismiss those ... not have sufficient connection with Philadelphia.* The cases include, ... al. (No. 140304328; Pa. Comm. Pls., Philadelphia Cty.), which ...
(Date:9/19/2014)... News) -- U.S. military troops deployed to sunny climates ... to a new study. Many returning troops ... some cases, military personnel developed blisters on their skin ... size of their moles since being deployed overseas. ... skin cancer, the study authors noted. "The past ...
(Date:9/19/2014)... 2014 (HealthDay News) -- Pregnant women who live in leafy, ... birth weight babies, a new study suggests. Researchers analyzed ... found that expectant mothers who lived in a neighborhood with ... percent lower risk of very preterm birth (before 30 weeks) ... (30 to 36 weeks). Babies born to mothers who ...
(Date:9/19/2014)... 19, 2014 (HealthDay News) -- The U.S. Food and Drug ... Thursday. Trulicity is part of a class of once-a-week injectable ... type 2 diabetes. "Trulicity is a new treatment ... treatment regimens to control blood sugar levels in the overall ... of the FDA,s Office of Drug Evaluation II, said in ...
Breaking Medicine News(10 mins):Health News:Melanoma risk found to have genetic determinant 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2Health News:Do Greener Neighborhoods Produce Healthier Babies? 2Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2
... a former psychiatric patient has been jailed for life for ... year in a Glasgow's Pollok Park. , ,He attacked ... from a psychiatric hospital where a judge had ordered he ... Robertson, a father of three from Glasgow, befriended James Smith ...
... consuming over eight cups of coffee a day risk spontaneous ... death was twice as likely among heavy coffee drinkers relative ... ,Adjusting for other risk factors weakened the association somewhat, ... of fetal death, Dr. Bodil Hammer Bech of the University ...
... findings that are being presented during the American Society ... Philadelphia, Pennsylvania, say that women are not being adequately ... Through analyses of the recently conducted renal trials showed ... may be the reason why the US Food and ...
... answer for may help cancer, researchers say.,A complex ... growth of tumours in tests in mice, reports online ... used by researchers in Gordon Jayson Manchester’s Christie’s Hospital ... During the tests, the sugar molecules were divided and ...
... have found a new model that shows how tumor ... the presence of microenvironment of tumor cells. // The ... cell to malignant cell is understood with the help ... new insights into the influence of the tumor cell ...
... training of new doctors in Britain. According to the Department of ... lack of cadavers and experts said more would be hit if ... ,The government has blamed rising medical student numbers, TV shows and ... years, the number of bodies being donated has fallen from 670 ...
Cached Medicine News:Health News:Man Bludgeons Friend, Gets Life Term 2Health News:Coffee In Pregnancy May Be Risky: Study 2Health News:New Model for understanding Tumor Metastasis 2
BD Vacutainer® Heparin Tubes are spray-coated with either lithium heparin or sodium heparin and are used for plasma determinations in chemistry....
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
... Coagulation tubes contain a buffered ... available with a citrate concentration ... 0.129 mol/l (3.8%). The mixing ... solution to 9 parts blood. ...
... are available in two versions. ... a clotting activator and is ... serum is required for testing ... is suitable where the testing ...
Medicine Products: